

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on December 19, 2007

TOWNSEND and TOWNSEND and CREW LLP

By: Ma Kan

PATENT  
Docket No.: 019904-003210US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Joseph K. Belanoff

Patent No.:

Issued:

Application No.: 10/533,146

Filed: April 27, 2005

For: METHODS FOR TREATING  
MIGRAINE

Confirmation No.: 5372

Examiner: June Marie Rogers

Art Unit: 4173

RESPONSE TO RESTRICTION  
REQUIREMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the election of species requirement mailed December 5, 2007, Applicants elect 17-beta-hydrox-17-alpha-19-(4-methyl-phenyl)-androsta-4,9 (11-dien-3-one). Applicants respectfully submit that the election is fully responsive to the requirement to elect a single species of steroidal glucocorticoid receptor antagonist devoid of progesterone receptor binding activity.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-273-7567.

Respectfully submitted,



Carol P. Johns  
Reg. No. 50,463

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300  
CPJ:cpj